|
US2020323842A1
|
|
Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
|
|
HU1900315A1
|
|
Industrial process for the preparation of high-purity estetrol
|
|
HU1900190A1
|
|
Selective histamine h3 receptor antagonists for treating autism spectrum disorder
|
|
HU1900193A1
|
|
Acid-addition salts of a selective histamin h3 receptor agonist and process for the preparation of them
|
|
HU1900121A1
|
|
Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
|
|
HU1900112A1
|
|
Improvement of affinity chromatography of immunoglobulins by using pre-capture flocculation
|
|
TW201938171A
|
|
Tricyclic compounds as vasopressin V1a receptor antagonists
|
|
HU1800376A2
|
|
Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture
|
|
HU1800333A2
|
|
Bicyclic derivatives as gabaa a5 receptor modulators
|
|
HU1800332A1
|
|
Tricyclic compounds ii
|
|
WO2019043635A1
|
|
D-amino acid oxidase activity inhibiting compounds
|
|
HU1800278A2
|
|
Process for the preparation of boc-linagliptin
|
|
HU1800275A2
|
|
Process for the multistep continuous-flow preparation of flibanserin
|
|
HU1800273A2
|
|
Stable pharmaceutical compositions and process for the preparation thereof
|
|
HU1800249A2
|
|
Thiadiazine derivatives
|
|
HU1800248A2
|
|
Spirochromane derivatives
|
|
HU1800250A2
|
|
Substituted (aza)indole derivatives
|
|
HU1800155A2
|
|
Preparation method of fulvestrant
|
|
HU1800007A2
|
|
Process for the preparation of 4-(4-aminophenyl) morpholin-3-one
|
|
HU1700521A2
|
|
Triazolobenzazepines
|
